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Abstract
The cytotoxicity of ceria ultimately lies in its electronic structure, which is defined by the crystal 
structure, composition, and size. Despite previous studies focused on ceria uptake, distribution, 
biopersistance, and cellular effects, little is known about its chemical and structural stability and 
solubility once sequestered inside the liver. Mechanisms will be presented that elucidate the in 
vivo transformation in the liver. In vivo processed ceria reveals a particle-size effect towards the 
formation of ultrafines, which represent a second generation of ceria. A measurable change in the 
valence reduction of the second-generation ceria can be linked to an increased free-radical 
scavenging potential. The in vivo processing of the ceria nanoparticles in the liver occurs in 
temporal relation to the brain cellular and protein clearance responses that stem from the ceria 
uptake. This information is critical to establish a possible link between cellular processes and the 
observed in vivo transformation of ceria. The temporal linkage between the reversal of the pro-
oxidant effect (brain) and ceria transformation (liver) suggests a cause–effect relationship.
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Introduction
Internalized ceria nanoparticles cause distinct cellular responses that can result in both 
therapeutic effects[1–7] and also oxidative stress.[8–11] Oxidative stress, which can be 
induced in the presence of free-radical species, is considered damaging to cells, proteins, 
and DNA.[8,12] Nanoparticle uptake[13–16] can result in free-radical formation and 
exacerbate cytotoxicity when cells are under constant exposure to oxidative stress.[17] When 
ceria nanoparticles (CeO2 NPs) are sequestered in a rat liver, cytotoxicity occurs, as 
evidenced by hepatocyte enlargement, sinusoidal dilatation, accumulation of Kupffer cells, 
and formation of granuloma.[18, 19] In fact, it was recently shown that CeO2 NPs uptake by 
the liver also coincides with early pro-oxidant effects in the rat brain,[20] which is followed 
by a transition to oxidative stress and then, unexpectedly, reverses back to no stress after 
ninety days.[21] Despite substantial studies that have focused on CeO2 NPs uptake, 
distribution, and biopersistance,[1–4,22, 23] so far, no information has been available on its 
chemical and structural stability once sequestered inside the liver, the organ that stores the 
greatest amount of CeO2 NPs. This raises questions about possible biotransformations of 
CeO2 NPs in the liver and what impact this may have on free-radical-mediated oxidative 
stress.
As a redox mediator, ceria can bind reactive oxygen species (ROS) such as O2•− and HO•− 
by reversibly shifting between oxidized (Ce4+) and reduced (Ce3+) forms.[1–4, 8, 24] Radical-
scavenging ability is significantly boosted at very small particle size.[1–4,6, 7] Moreover, the 
free-radical scavenging ability of CeO2 NPs was shown to protect against ischemic stroke in 
an in vivo model,[2] and recently, protein-coated CeO2 ‘nano-truffle’ NPs were shown to 
have excellent redox enzyme activity that resulted in enhanced free-radical scavenging.[1–3] 
Therefore, it is important to determine the mechanisms that govern cellular responses and 
the role CeO2 NPs play. Herein, we report for the first time that intravenously administered 
CeO2 NPs after ninety days undergo in vivo processing inside the rat liver causing a shift 
towards smaller particle size and increased reactive surface area. Detailed analyses of the 
redox activity of the in vivo processed ceria nanoparticles are presented.
Results and Discussion
Nanoceria
The original intravenously administered CeO2 NPs were cubes with (100) crystal faces (see 
Figure 1 and Figure S1 in the Supporting Information) and a size range of approximately 
(31±4) nm as determined by dynamic light scattering, and were synthesized by means of a 
hydrothermal precipitation method, filtered, sterilized, and sonically redispersed in aqueous 
solution with a citrate capping agent to obtain a 5% ceria aqueous dispersion, which was 
then intravenously (iv) infused into male Sprague Dawley rats (Figure S2; 85 mg kg−1).[24] 
The high dose is well outside the previously determined therapeutic window for ceria in 
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vivo[3] and was mainly used because of our previous study that was centered on 
characterizing the safety and toxicity of nanoceria.[22–24] Details of CeO2 NPs distribution, 
clearance, and biopersistance are described elsewhere.[22, 23] Liver-tissue sections were 
scanned for the occurrence of CeO2 NPs and any tissue alterations that resulted after ninety 
days (Figure S2, which shows light microscopy and Figures S3, S5, and S6 for transition 
electron microscopy (TEM)). The CeO2 NPs formed agglomerates in the liver up to day 
thirty, but otherwise showed no indication of breakdown or chemical 
transformation.[18, 19,21] However, after ninety days inside the liver, the iv-infused cube-
shaped CeO2 NPs (Figure 1a) had become highly fragmented and rounded along their edges 
(Figure 1b), which indicated that in vivo processing of the particles had occurred. Moreover, 
accumulations of copious ultrafine (1–3 nm) crystallites that formed in the liver within close 
proximity to the rounded CeO2 NPs were discovered for the first time and labeled as CeO2 
clouds (Figure 1c, d). These second-generation ceria particles (crystallites in CeO2 clouds) 
seem to be trapped in ‘groups or swarms’ owing to fast precipitation, which favors the 
formation of the CeO2 clouds near the vicinity of the parent particles, and there is clearly an 
analogy with the formation of other oxide nanoparticles seen in human lung fibroblasts.[25]
The CeO2 clouds consist of discrete 1–3 nm CeO2 NPs with a cross-lattice pattern (Figure 
1d). Corresponding electron-diffraction ring patterns (selected-area electron diffraction 
(SAED)) were used in conjunction with known diffraction patterns from CeO2 as a 
fingerprint for phase identification of the CeO2 clouds (PCED2.0), which revealed dominant 
(111), (200), and (311) faces that are not prominently seen with the as-synthesized cubes 
(Figure 1d). Polycrystalline large CeO2-grains after Ostwald ripening were also observed 
(Figure S3). The hydrothermally derived ceria used in the iv infusions represent a group 
rather than all types of ceria used in industry today and the in vivo performance of 
industrially significant ceria from commercial applications (typically high-temperature 
processes, that is, combustion[26]) may be different from those of the current hydrothermal 
ceria and, therefore, also need to be systematically investigated. Such studies will help to get 
a clearer understanding of the roles that nanostructures play after particle exposure and 
uptake.[26] The hydrothermal ceria were chosen because of their narrow size range and cube 
shape to be more easily recognizable in vivo.
Redox potential of second-generation nanoceria formed inside the liver
For the first time, ceria is shown to undergo a size transformation inside the liver as 
demonstrated by the formation of very small 1–3 nm CeO2 NPs, and at such a small scale 
ceria is well known to have therapeutic activity in free-radical reduction.[1, 2, 5–7] Briefly, 
the autocatalytic ability of ceria to shift between Ce4+ and Ce3+ in the crystal lattice relies on 
the concentration of surface defects or oxygen vacancies in the outer surface layer of 
crystals,[27] and, in the case of ultrafines, the entire crystallites will have defects (CeO2−x) 
that may further augment the reducing activity of the CeO2−x NPs.[28] Particles smaller than 
4 nm were found previously to be completely reduced to CeO1.5 NPs and have a fluorite 
structure that is essentially the same as that of CeO2 NPs.[27, 28] In other words, the valence 
of Ce ions in ultrafine CeO2−x NPs is a function of their particle size.[27, 28] The redox 
potential of CeO2−x NPs both after hydrothermal synthesis and after in vivo processing in 
the liver was assessed with electron energy-loss spectroscopy (EELS, see Figure S4). EELS 
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measurements with great spatial resolution (nanoprobe ≈0.15 nm; collection angle, 30 
mrad) in high-resolution scanning mode (scanning transmission electron microscopy 
(STEM)) allowed for specific nanoparticles to be analyzed (Figure 2). Only short electron-
beam irradiation was allowed to avoid thermal damage that has been shown to alter the 
valence of Ce ions from Ce4+ to Ce3+ caused by loss of oxygen from the crystal lattice.[27] 
To analyze the valence of Ce, EELS spectra containing the Ce M4,5-edge with information 
on the spin–orbital 4f occupancy (M4 edge at 901 eV (3d3/2 →4f5/2) and M5 edge at 893 eV 
(3d5/2 →4f7/2)) were obtained as a relative measure of CeO2−x NPs valence states.[27, 28] 
The ratios in M5/M4 line edges are used to obtain the valence of cerium ions and the 
intensity of the M4 edge is higher than that of M5 when Ce4+ is dominant, whereas the 
reverse occurs when Ce3+ is dominant. Spectra were taken from the edge (surface region) 
and the core of larger particles to obtain Ce3+/Ce4+ ratios. Both synthesized CeO2 NPs 
(Figure 2a) and those that had undergone in vivo processing (rounding) in the liver (Figure 
2b) were analyzed. For the in vivo rounded grains we first visually identified particles that 
were significantly affected during the biotransformation and then examined the local redox 
variations within single grains (Figure 2b, c, d). For the very small 1–3 nm crystallites in 
CeO2 clouds we could only obtain a Ce3+/Ce4+ ratio for the whole particle (Figure 2d). The 
representative Ce M4,5-edge spectra for the freshly synthesized cubes (Figure 2a) and in 
vivo rounded grains (Figure 2b) included both surface and core analyses. The core region of 
both fresh and in vivo processed grains always showed characteristic satellite peaks (Figure 
2a, b), which suggests a highly equilibrated content of Ce4+ while the surfaces of the same 
particles are high in Ce3+. This is in good agreement with a previous study for Ce3+/Ce4+ 
variations in nanoceria.[28–31] All CeO2 surfaces in this study had M5/M4 ratios ranging 
between 1.1 and 1.4, and the core regions averaged approximately 0.9 for the cubes (Figure 
2c) and approximately 0.92 for the in vivo processed grains (Figure 2d), which is close to 
equilibrated ceria. The M5/M4 ratio was computed by fitting Gaussians to the M5 and M4 
peaks and computing the Gaussian amplitude ratios. Figure 2c, d display the computed 
M5/M4 ratio plots for representative EELS profiles that were acquired by analyzing 
nanoparticle cross-sections before (Figure 2c) and after (Figure 2d) in vivo processing. A 
significant enrichment in Ce3+ is always observed in surface layers whereas the core regions 
are primarily Ce4+ (reduction potential of as-synthesized ceria cubes and that of processed 
rounded grains in the liver are essentially the same). However, EELS analyses of ultrafines 
(≈ 1–3 nm) from CeO2 clouds had much weaker M4 lines and lacked satellite peaks (Figure 
2e). Figure 2e shows representative M5 and M4 lines for 1, 2, and 3 nm particles from the 
CeO2 clouds that indicate a reduced valence (Ce3+) state for the entire grains (particles were 
too small for line profiles). A total of fifty crystallites had a range from 38 to 70 % Ce3+, 
which indicates that CeO2 cloud formation shifts the overall redox activity of ceria to a more 
reduced state and, thus, higher free-radical scavenging activity. The increase in oxygen 
vacancies in the crystal lattice of CeO2 cloud particles is also demonstrated by variations in 
the oxygen K-edge (Figure S4).
In vivo processing mechanisms of nanoceria
A mechanism for the in vivo processing and rounding of the iv-infused CeO2 NPs could be a 
partial dissolution of high-energy edge sites. So far, dissolution rates of CeO2 thin films 
have been measured for various acidic[32] (i.e., HCl and H2SO4) and oxidizing (addition of 
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H2O2)[32] media, despite common views that CeO2 is a highly insoluble refractory oxide.[33] 
Furthermore, uptake and biotransformation of CeO2 NPs in a recent cucumber-plant system 
led to Ce phosphate rods in intercellular spaces.[34] We also show formation of rod-shaped 
crystallites in the liver near in vivo processed CeO2 NPs; they are composed of Ce, O, and P 
as shown in TEM and corresponding energy-dispersive X-ray spectroscopy (EDS) analyses 
(Figure 1e; Figure S5) and are of comparable size and morphology as sol–gel-derived Ce 
phosphates.[35] Since significantly more CeO2 clouds formed in the liver than in the spleen 
(even though the spleen had sequestered approximately the same amount of CeO2 NPs 
(Figure S6)), it is possible that the liver environment promotes the processing of CeO2 NPs 
through its localized liver acid–base physiology (cellular pH is tightly regulated and the 
CeO2 NPs would primarily encounter a low pH in lysosomes). Oxidation of carbohydrates 
and fat typically results in H+ and HCO3− production, which can feasibly affect partial 
dissolution of sequestered CeO2 NPs based on earlier solubility studies.[32, 34,35] The in situ 
formation of CeO2 clouds, therefore, could be governed by the release of Ce ions derived 
from dissolving iv-infused ceria in the liver since the ceria dissolution rate is a function of 
local pH and electrochemical potential.[32] Many ceria catalyst investigations have 
convincingly established the surface reduction of small ceria particles during, for example, 
water–gas shift (WGS) reactions[36] and in one view[37] CeO2 NPs with high Ce3+ surface 
concentration may be oxidized leading to a metastable Ce4+ complex [see the Supporting 
Information; Eqs. (1)–(3) are an extension of redox reactions observed during WGS 
catalysis of ceria]. ROS, particularly hydroxyl radicals (OH•), can react with surface geminal 
hydroxides of the high-energy CeO2-edge sites, which could release an [O=CeO2H]• radical 
and additional water. To form monomer Ce oxyhydroxide (O=Ce(OH)2), the released 
[O=CeO2H]• radical would have to react with a hydrogen radical and the monomer Ce 
oxyhydroxide could then oligomerize to the intermediate dimer, followed by 
oligomerization to higher-molecular-weight seed nuclei (and then nanoparticles in clouds) 
and additional free water [see the Supporting Information; Eqs. (4)–(6)]. In vivo processing 
leads to a much greater reactive ceria surface area in the second-generation ceria (CeO2 
clouds). EELS of the cloud particles demonstrated that the oxidation state, when compared 
with the original ceria, is more reduced and we suggest that in vivo processing is a function 
of 1) the acidic environment, 2) the oxidizing potential of the environment, and 3) the 
exposure time (it took ninety days before the effects of in vivo processing were recognized 
in tissue samples).
At this point it is important to better understand the oxygen-tuning capability of ultrafines in 
the liver (second-generation ceria). We set out to determine how fast the second-generation 
ceria, after exposure to an oxidant (ceria acts like an oxygen scrubber), would be able to 
return back to the reduced state (Ce4+→Ce3+), since EELS demonstrated that all particles in 
the second-generation ceria clouds were in a reduced state. An earlier study on synthesized 
ceria focused on the oxidation (Ce3+→Ce4+) of ultrafines and used high-resolution X-ray 
photoelectron spectroscopy (XPS) to evaluate the redox state before and after incubation of 
the nanoparticles with hydrogen peroxide.[38] Since XPS could not be performed directly on 
CeO2 clouds because nanoparticles cannot be isolated because of strong liver tissue 
interactions, we synthesized 2–4 nm CeO2 NPs to resemble the crystallites in CeO2 clouds 
(Figure 1b, f). To mimic the redox activity of the CeO2 clouds we first followed previously 
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reported oxidation experiments[38] (using 0.5 M H2O2 that quickly evaporated) and oxidized 
the particles. The Ce3+/Ce4+ ratios and concentration of Ce3+ were determined using 
integrated peak areas. (PAS energy of 50 eV: six peaks associated with Ce4+ (binding 
energy (BE) at 882.1, 888.0, 898.1, 900.9, 906.3, and 916.3 eV) and four with Ce3+ (BE at 
880.2, 886. 0, 903.2, and 905.0 eV) were used for the deconvolution). Immediately after 
oxidation, the XPS spectrum had no peaks associated with Ce3+ (Figure 3), which is 
consistent with previous studies that showed ultrafine ceria convert the maximum amount of 
oxygen into available oxygen vacancies in the ceria lattice in the presence of an external 
oxidant.[38] We observed that the 2–4 nm ceria had approximately 40 % Ce3+ before H2O2 
exposure and approximately 0 % Ce3+ afterwards, and furthermore in less than 1 h 
transitioned back to the pre-H2O2 baseline composition (Figure 3). Our study shows that 
oxidized ultrafine ceria return quickly and completely to the reduced state without the 
presence of reducing agents (Figure 3). The in vivo transformation and reducing potential of 
ultrafine CeO2 in the liver is shown in the predictive model in Figure 4, which suggests four 
key steps including: 1) nanoparticle sequestration in a complex acid–base-controlled 
environment (liver) with some dissolution of original particles; 2) in situ formation of 
second-generation ceria (CeO2 clouds); 3) greater reactive surface area for the second-
generation ceria inside CeO2 clouds; and 4) higher Ce3+ associated with second-generation 
ceria. We propose that the in vivo transformation of ceria is a dynamic system (Figure S7).
Our earlier reported results on the brain cellular responses that stemmed from the uptake of 
CeO2 NPs by the liver,[21] and occurred in the same experimental system as the current 
study, were included in the predictive model (Figure 4). The model establishes a temporal 
link between cellular processes in the brain[21] and the in vivo transformation of ceria in the 
liver. Prior to in vivo processing of ceria, oxidative stress gradually increased in ceria-
treated rats and brain cellular stress (stage S1; 1 h–1 d; antioxidant defense) was then 
followed by brain inflammation (stage S2; 1–7 d; pro-inflammatory response) and then 
brain-cell death (stage S3; 7–30 days; mitochondrial-mediated cytotoxic effects).[21] There 
is an analogy with a published hierarchical model,[9] however, after ninety days an 
unexpected brain cellular clearance response was reported,[21] which is shown in the model 
at stage S4 (30–90 days) and indicates a reversal or decrease in oxidative stress.[21] The 
model also includes the index of cellular redox status that was obtained from the ratio of 
oxidized glutathione (GSSG) to reduced glutathione (GSH);[21] reduced GSH constitutes 
approximately 98 % of cellular GSH in the absence of cellular stress and GSSG/GSH 
typically increases under conditions in which cellular redox potential in pathological tissues 
is compromised.[39] Brain oxidative stress is shown to have increased as early as one hour 
after CeO2 NPs infusion (signaling pathway: Nrf-2), and one day later triggered brain 
inflammation (signaling pathway: TNFα (NF-kB IL-1b)).[21] The model also shows that 
between seven and thirty days, inflammation is significantly increased in the hippocampus, 
cortex, and cerebellum, and brain-cell death occurs at thirty days (signaling pathway: pro-
apoptotic; Pro-Caspase-3), and then followed by autophagy (LC-3AB), and finally returns to 
normal levels at ninety days.[21] Importantly, the late cellular and protein-clearance response 
previously observed in the rat brain[21] coincides with the inception of in vivo processing of 
CeO2 NPs as shown in the predictive model (Figure 4). Since the processed nanoparticles in 
the liver (second-generation ceria) were shown to have high Ce3+, they may also have a high 
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affinity for reactive oxygen species and free-radical scavenging activity. Although the 
mechanisms are not established at this time, it could be anticipated that the in vivo 
processing of ceria has far-reaching protective effects, as was observed with the reversal in 
pro-oxidant brain effects.[2, 21]
Conclusion
In conclusion, we have demonstrated that iv-infused ceria nanoparticles, after prolonged 
residence time in the liver (90 days), undergo in vivo processing. This transformation 
includes a particle-size effect towards ultrafines (second-generation ceria), combined with a 
measurable change in the valence reduction and redox activity that can be linked to the free-
radical scavenging activity of ceria in a previous study.[1–7,21] This is the first record to 
show that ceria undergoes partial dissolution inside the liver and the consequences of this 
are far-reaching since cerium ions presumably can be more mobile than nanoparticles and 
also have different cytotoxicity effects.[40–42] It will be important to determine the transport 
properties of released cerium ions and the potential precipitation mechanisms or any other 
mechanisms that lead to the second-generation ceria both interior and exterior of the liver. 
This information will be critical to establish a direct linkage between cellular processes like 
the reversal in pro-oxidative stress in the brain[21] and in vivo processing and transformation 
of ceria. The fact that the second-generation ceria were found as very small particles 
grouped together in clouds or swarms suggests some type of in vivo controlled surface 
functionalization.[1, 3, 17, 43–45] The long-term ceria in vivo effects may be described as a 
dynamic system that alters and redistributes ceria. This could be a step towards improving 
ceria biocompatibility in vivo.
Experimental Section
All experimental conditions, sample preparation, and analysis procedures are listed in detail 
in the Supporting Information. This includes material and synthesis procedures for ceria; 
hydrothermal synthesis conditions and nanoparticle-coatings preparations; characterization 
of Ce concentrations and dispersion using inductively coupled plasma mass spectrometry 
(ICP-MS) analysis; light microscopy of ceria and tracking the nanoparticles in liver tissue; 
high-resolution TEM and STEM imaging and EELS analysis of the CeO2 NPs; and XPS 
analyses. A detailed description of the animal care, ceria infusion into rats, animal 
termination and tissue harvesting, and histopathology analysis is also included with 
information on how the distribution of CeO2 NPs in organs was obtained.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HRTEM images of the ceria nanoparticles: (a) as-synthesized CeO2 NPs with (100) faces 
and (b) rounded CeO2 NPs after in vivo processing in liver; (c) STEM image of a liver 
section with CeO2 NPs and ultrafine CeO2 clouds (inside yellow line); (d) HRTEM image: 
ultrafine crystallites from CeO2 clouds; the inset shows electron-diffraction rings with 
dominant (111) and (200) faces, which indicate that particles in the clouds are well 
crystallized; (e) STEM image of rod-shaped crystals; the inset is the EDS analysis with Ce-
O-P composition; (f) HRTEM image: synthesized 2–4 nm CeO2 crystallites; the inset shows 
that the electron-diffraction rings are the same as those of the CeO2 clouds in (d).
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EELS analysis of CeO2 NPs: (a) the as-synthesized CeO2 cubes; (b) in vivo processed ceria 
after 90 d in the liver; (c) M5/M4 ratio from the line profile of as-synthesized CeO2 NPs; (d) 
M5/M4 ratio from the line profile of rounded in vivo processed CeO2 NPs; (e) representative 
M4 and M5 lines for individual 1, 2, and 3 nm crystallites (in CeO2 clouds. which indicate 
enhanced +3 reduction as a function of particle size.
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XPS spectra of synthesized ultrafine CeO2 NPs: (a) high-resolution Ce(3d) spectra of 
ultrafine (2–4 nm) synthesized CeO2 NPs at three different stages: as-prepared (≈ 40 % 
Ce3+), after oxidation with H2O2 (≈ 0% Ce3+), and after 1 h elapsed past oxidation with 
H2O2 (≈ 40 % Ce3+). As-prepared and H2O2-treated samples after approximately 1 h show 
identical survey spectra.
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Predictive in vivo processing model of CeO2 in the rat liver is shown in temporal relation to 
brain effects after intravenous administration of 30 nm CeO2. The top part illustrates 
signaling pathways (Nrf-2; NF-kB, pro-apoptotic, autophagy) with measured GSSG:GSH 
from our previous study[21] for three brain regions (neon-green =hippocampus; olive-green 
= - cortex; purple =cerebellum) taken at different time intervals ranging from 1 h to 90 d. 
The bottom part illustrates in vivo processing of CeO2 in the liver during the same time 
intervals with formation of CeO2 clouds (second-generation ceria). Four distinct stages (S1–
S4) are indicated for both the brain and liver. CeO2 cloud formation at 90 d coincides with 
measured loss of the pro-oxidant effect in brain.
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